Medications as a Risk Factor for Fragility Hip Fractures: A Systematic Review and Meta-analysis
- 1 July 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Calcified Tissue International
- Vol. 107 (1), 1-9
- https://doi.org/10.1007/s00223-020-00688-1
Abstract
Fragility hip fractures and their associated morbidity and mortality pose a global healthcare problem. Several pharmaceutical products have been postulated to alter bone architecture and contribute to fragility hip fractures. We searched four electronic databases from inception to September 2017. Inclusion criteria were the following: (1) adult patients with fragility hip fractures, (2) full text in English, (3) minimum one-year follow-up, and (4) reporting of at least one risk factor. To minimize heterogeneity among the studies, we performed subgroup analyses. Whenever heterogeneity remained significant, we employed random effect meta-analysis for data pooling. Thirty-eight studies were included, containing 1,244,155 subjects and 188,966 cases of fragility hip fractures. Following medications were significantly associated with fragility hip fractures: Antidepressants (OR 2.07, 95% CI 1.98-2.17), antiparkinsonian drugs (OR 2.21, 95% CI 1.15-4.24), antipsychotic drugs (OR 2.0, 95% CI 1.50-2.66), anxiolytic drugs (OR 1.44, 95% CI 1.19-1.75), benzodiazepines (OR 1.84, 95% CI 1.26-2.69), sedatives (OR 1.33, 95% CI 1.14-1.54), systemic corticosteroids (OR 1.65, 95% CI 1.37-1.99), H-2 antagonists (OR 1.21, 95% CI 1.18-1.24), proton pump inhibitors (OR 1.41, 95% CI 1.16-1.71), and thyroid hormone (OR 1.29, 95% CI 1.13-1.47). Hormone replacement therapy with estrogen (HRT) was associated with decreased risk of hip fracture (OR 0.80, 95% CI 0.65-0.98). There are several medications associated with sustaining a fragility hip fracture. Medical interventions should be considered for patients on these medications, including information about osteoporosis and fracture prevention.This publication has 75 references indexed in Scilit:
- Diuretic initiation and the acute risk of hip fractureOsteoporosis International, 2012
- The Levels of Evidence and Their Role in Evidence-Based MedicinePlastic and Reconstructive Surgery, 2011
- Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control studyOsteoporosis International, 2010
- Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk PatientsGastroenterology, 2010
- Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control studyOsteoporosis International, 2010
- Antipsychotic use and the risk of hip/femur fracture: a population-based case–control studyOsteoporosis International, 2009
- Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older AdultsCalcified Tissue International, 2008
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- Factors Associated With 5-Year Risk of Hip Fracture in Postmenopausal WomenJAMA, 2007
- Preventing fragility hip fracture in high risk groups: an opportunity missedHeart, 2006